Rosuvastatin weight loss
Searched over 200M research papers
Summary
10 papers analyzed
Some studies suggest rosuvastatin improves insulin sensitivity, glucose intolerance, and fat distribution without affecting body weight or fat loss, while other studies show mixed results regarding weight gain and lean body mass improvement.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Rosuvastatin and Weight Loss: A Comprehensive Review
Introduction to Rosuvastatin and Its Primary Uses
Rosuvastatin is a statin medication primarily used to treat dyslipidemia by lowering low-density lipoprotein (LDL) cholesterol levels. It is known for its efficacy in reducing cholesterol and improving cardiovascular health. However, its effects on body weight and fat distribution have also been explored in various studies.
Rosuvastatin and Insulin Sensitivity in High-Fat Diet Models
Research has shown that rosuvastatin can improve insulin sensitivity in rats fed a high-fat diet (HFD). In one study, rosuvastatin treatment normalized several key mediators involved in glucose metabolism and stress signaling pathways, such as SIRT-1, p53, PGC-1α, PPAR-γ, and GLUT-4 in white adipose tissue (WAT). Despite these metabolic improvements, the study concluded that rosuvastatin did not significantly affect body weight or WAT loss in these rats.
Rosuvastatin's Impact on Body Weight and Fat Distribution
Several studies have investigated the effects of rosuvastatin on body weight and fat distribution. In a study involving diet-induced obesity (DIO) in mice, rosuvastatin treatment resulted in decreased fat tissue weight and adipocyte size, accompanied by an overall tendency towards body weight loss. This suggests that rosuvastatin may help reduce fat accumulation and improve metabolic health in obese models.
Another study on C57Bl/6 mice fed a high-fat diet found that rosuvastatin treatment decreased adiposity and adipocyte size, particularly in visceral fat depots. The study also noted a redistribution of fat from visceral to subcutaneous depots, which is considered beneficial for metabolic health. This redistribution was associated with improved glucose tolerance and insulin sensitivity.
Rosuvastatin and Weight Gain Prevention in Combination Therapies
In a study comparing the effects of simvastatin, rosuvastatin, and fenofibrate on female rats treated with oral contraceptives and a high-fat diet, rosuvastatin was found to inhibit significant rises in triglyceride and total cholesterol levels. However, only fenofibrate was effective in preventing significant weight gain, indicating that while rosuvastatin has beneficial effects on lipid profiles, its impact on weight gain prevention may be limited.
Long-Term Effects on Lean Body Mass
A study on HIV-infected adults on antiretroviral therapy examined the long-term effects of rosuvastatin on bone, muscle, and fat. Over 96 weeks, rosuvastatin was associated with a trend towards increased lean body mass (LBM) without significant changes in body fat. This suggests a potential benefit of rosuvastatin in preserving muscle mass, which is crucial for overall metabolic health and aging.
Conclusion
While rosuvastatin is primarily used for its cholesterol-lowering effects, research indicates that it may also influence body weight and fat distribution. Studies have shown that rosuvastatin can improve insulin sensitivity and reduce fat tissue weight in obese models, although its impact on overall body weight loss is less clear. Additionally, rosuvastatin may help preserve lean body mass over long-term use. These findings highlight the potential metabolic benefits of rosuvastatin beyond its primary use in managing dyslipidemia.
Sources and full results
Most relevant research papers on this topic
